Koyfin Home > Directory > Health Care > Horizon Therapeutics > EV / EBITDA (ntm)

Horizon Therapeutics EV / EBITDA (ntm) Chart (HZNP)

Horizon Therapeutics annual/quarterly EV / EBITDA (ntm) from 2014 to 2020. Enterprise multiple, also known as the EBITDA multiple, is a ratio used to determine the value of a company. It uses the consensus estimate EBITA over the next twelve months (NTM). The enterprise multiple looks at a firm in the way a potential acquirer might by considering the company's debt, which other multiples such as P/E do not include.
  • Horizon Therapeutics EV / EBITDA (ntm) for the quarter ending December 12, 2020 was 12.21 a -3.99% decrease of -0.49 year over year
  • Horizon Therapeutics EV / EBITDA (ntm) for the last 12 months ending December 12, 2020 was 12.21 a -3.99% decrease of -0.49 year over year
  • Horizon Therapeutics Annual EV / EBITDA (ntm) for 2020 was 12.21 a 2.46% increase of 0.30 from 2019
  • Horizon Therapeutics Annual EV / EBITDA (ntm) for 2020 was 11.91 a 1.53% increase of 0.18 from 2019
  • Horizon Therapeutics Annual EV / EBITDA (ntm) for 2020 was 11.72 a -8.28% decrease of -0.97 from 2019
Other Valuation Metrics:
  • Horizon Therapeutics Market Cap for the quarter ending March 03, 2018 was $2,337m a 17.35% increase of 406m year over year
  • Horizon Therapeutics Price / Book for the quarter ending March 03, 2018 was 2.36 a 32.03% increase of 0.75 year over year
  • Horizon Therapeutics Enterprise Value for the quarter ending March 03, 2018 was $3,487m a 7.74% increase of 270m year over year
View Chart On Koyfin

Quarterly HZNP EV / EBITDA (ntm) Data

12/202012.21
12/202011.91
12/202011.72
11/202012.69
11/202012.72
11/202012.40
11/202012.43
11/202012.62
11/202012.64
11/202012.82

Annual HZNP EV / EBITDA (ntm) Data

202012.21
202011.91
202011.72
202012.69
202012.72
202012.40
202012.43
202012.62
202012.64
202012.82